Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy and Pfizer Settle Lipitor Litigation

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies

You may also be interested in...



Ranbaxy Launches AG Version Of Caduet As CEO Likens Lipitor Deal With Teva To An Insurance Policy

Both Ranbaxy and Mylan appear to have agreed to sell all doses of Caduet under separate authorized generic deals with Pfizer.

A Big Hit But A Small Miss? Ranbaxy’s Caduet Prospects In Doubt As Mylan Storms The Market

A rollercoaster of a week for India’s Ranbaxy ends with yet another mystery – what is the status of its first-to-file applications for Pfizer’s Caduet?

A Big Hit But A Small Miss? Lipitor Generic Launched But Ranbaxy’s Caduet Prospects In Doubt As Mylan Storms The Market

A rollercoaster of a week for India’s Ranbaxy ends with yet another mystery – what is the status of its first-to-file applications for Pfizer’s Caduet?

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel